Affiliation:
1. Pharm D V year, Narayana Pharmacy College.
2. Principal Narayana Pharmacy College
3. Asst Prof Narayana Pharmacy College.
Abstract
Selective serotonin reuptake inhibitors (SSRI's) are the most commonly prescribed antidepressants. They are mainly prescribed to treat depression.
SSRI's are considered to be safer and generally cost effective when compared to some newer antidepressant classes. SSRI's acts by inhibiting the
serotonin transporter (SERT) at the presynaptic axon terminal. A number of factors must be considered when evaluating SSRI's. An SSRI drug
utilization study is performed for further evaluation. The study was a prospective obs Methodology: ervational study on “Utilization and
Evaluation of SSRI's in Psychiatry Patients”, which was carried out in the 'Department of Psychiatry' in a Secondary care teaching hospital of South
India. Study the maximum number of patients was 786 and the age groups of 981 out of which m Results: aximum were of age group 46-54 and
minimum were above 60, the female were more suffered in that maximum were married and the educational levels of the patients were mostly
secondary, the hygienic conditions, surroundings and cleanliness were good. Discussion: Recent studies also found that mostly used SSRIs are
Fluoxetine, Paroxetine, Citalopram and Sertraline. We found that in our hospitals the data reveals the status for some mostly used Fluoxetine as 386
(49.10%) and Paroxetine 288 (36.64%). Conclusion: Our study concluded that most of the patients suffered with psychological conditions and
symptoms are considered. After using SSRI their overall effect in the patient health and outcome was observed with better outcome.
Reference27 articles.
1. World Health Organization (WHO). Depression and other common mental disorders: global health estimates,http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER2017.2-eng.pdf (accessed 27 August 2017)
2. Hardeveld F, Spijker J, De Graaf R, et al. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand 2010; 122: 184–191.
3. Peselow ED, Tobia G, Karamians R, et al. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up. Psychiatry Res 2015; 225: 680–686.
4. Spijker J, van Straten A, Bockting CL, et al. Psychotherapy, antidepressants, and their combination for chronic major depressive disorder: a systematic review. Can J Psychiatry 2013; 58: 386–392.
5. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new generation antidepressants: a multiple-treatments meta-analysis. Lancet (London, England) 2009; 373: 746–758.